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Abstract
Aims/hypothesis MicroRNAs are key regulators of gene ex-
pression involved in health and disease. The goal of our
study was to investigate the global changes in beta cell
microRNA expression occurring in two models of obesity-
associated type 2 diabetes and to assess their potential con-
tribution to the development of the disease.
Methods MicroRNA profiling of pancreatic islets isolated from
prediabetic and diabetic db/dbmice and frommice fed a high-fat
diet was performed by microarray. The functional impact of the
changes in microRNA expression was assessed by reproducing
them in vitro in primary rat and human beta cells.
Results MicroRNAs differentially expressed in both models
of obesity-associated type 2 diabetes fall into two distinct
categories. A group including miR-132, miR-184 and miR-
338-3p displays expression changes occurring long before the
onset of diabetes. Functional studies indicate that these ex-
pression changes have positive effects on beta cell activities
and mass. In contrast, modifications in the levels of miR-34a,
miR-146a, miR-199a-3p, miR-203, miR-210 and miR-383 pri-
marily occur in diabetic mice and result in increased beta cell
apoptosis. These results indicate that obesity and insulin resis-
tance trigger adaptations in the levels of particular microRNAs to
allow sustained beta cell function, and that additional microRNA
deregulation negatively impacting on insulin-secreting cells may
cause beta cell demise and diabetes manifestation.
Conclusions/interpretation We propose that maintenance of
blood glucose homeostasis or progression toward glucose in-
tolerance and type 2 diabetes may be determined by the balance
between expression changes of particular microRNAs.
Keywords Apoptosis . Beta cell . Diabetes . High-fat diet .
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Abbreviations
cMET Met proto-oncogene (hepatocyte growth factor
receptor)
GSK-3β Glycogen synthase kinase 3 β
HFD High-fat diet
miRNA microRNA
mTOR Mammalian target of rapamycin
PRL Prolactin
qRT-PCT Quantitative RT-PCR
Introduction
Type 2 diabetes is characterised by insulin resistance of
target tissues and insufficient insulin secretion from pancre-
atic beta cells to meet the organism’s needs. Insulin resis-
tance is normally compensated by expansion of the beta cell
mass and a rise in the insulin secretory activity [1]. However,
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in predisposed individuals this compensatory process fails,
resulting in beta cell dysfunction, eventually accompanied by
reduction of the beta cell mass and type 2 diabetes manifesta-
tion [2]. A better knowledge of the molecular mechanisms
underlying beta cell adaptation and failure will be instrumental
for designing new strategies to prevent or treat this disease.
MicroRNAs (miRNAs) are small non-coding RNAs that
play central roles in a number of physiological and pathological
processes [3]. Several studies have shown that miRNAs partic-
ipate in the control of beta cell differentiation, function and
mass. These non-coding RNAs regulate insulin production by
directly or indirectly affecting the expression of key transcrip-
tion factors and they contribute to fine-tuning of hormone
release by modulating the levels of important components of
the beta cell secretory machinery [4]. The expression of several
miRNAs is affected by prolonged exposure to elevated con-
centrations of glucose, NEFA and proinflammatory cytokines
[4]. Moreover, alterations in the levels of many islet miRNAs
have been reported in different models of diabetes [5–9].
However, the functional impact of these miRNA expression
changes and their potential role in the development of diabetes
were, in most cases, not explored.
In this study, we analysed the global variations in islet
miRNA expression in prediabetic and diabetic db/db mice
[10] and in mice fed a high-fat diet (HFD) [11]. Differentially
expressed miRNAs in these models of obesity-associated dia-
betes were systematically investigated for their effects on rat
and human beta cell function and for their impact on cell
survival on chronic exposure to pro-apoptotic conditions. The
results indicate that specific changes in islet miRNA expression
in prediabetic and diabetic states reflect the coexistence of
adaptive processes elicited to compensate insulin resistance
and of pathological reactions promoting beta cell failure. The
balance between these opposing phenomena is likely to deter-
mine progression from normoglycaemia to hyperglycaemic
states and the manifestation of diabetes.
Methods
Materials TNFα and INFγwere obtained fromR&DSystems
(Minneapolis, MN, USA). IL-1β, prolactin (PRL), exendin-4
and palmitate were purchased from Sigma-Aldrich (St Louis,
MO, USA).
Animals Prediabetic (6 weeks old) and diabetic (14–20 weeks
old) C57BL/KsJ db/db mice and age-matched C57BL/KsJ
control animals were obtained from the Garvan Institute
breeding colonies (Sydney, NSW, Australia) [10]. Five-
week-old male C57BL/6 mice were purchased from Charles
River Laboratories (Saint-Constant, QC, Canada) and fed a
normal diet or HFD (Bio-Ser Diet number F3282,
Frenchtown, NJ, USA; 60% [wt/wt] energy from fat) for
8 weeks as described [11]. Male Wistar rats were purchased
from Charles River Laboratories (L’Arbresle, France). All
animal procedures were performed in accordance with
National Institutes of Health (NIH) guidelines and were ap-
proved by the respective Australian, Canadian and Swiss
research councils and veterinary offices.
Microarray profiling Total RNAwas isolatedwith themirVana
RNA isolation kit (Ambion, Austin, TX, USA) from islets of
C57BL/KsJ db/dbmice or control animals. Total RNA from islets
of C57BL/6 mice fed a normal diet or HFDwas isolated with the
miRNeasy kit (Qiagen, Hombrechtikon, Switzerland). Global
miRNA expression profiling was carried out at the Genomic
Technologies Facility of the University of Lausanne using
miRNA gene microarrays (Agilent Technologies, Morges,
Switzerland). Microarrays included probes for mouse miRNAs
listed on www.mirbase.org/ (release 14, 2009).
Isolation and culture of dissociated islet cells Pancreatic islets
were isolated as described previously [12] by collagenase diges-
tion followed by purification on a Histopaque (Sigma-Aldrich)
density gradient. The islets were first cultured overnight in RPMI
1640 Glutamax medium (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% (vol./vol.) FCS (Amimed,
BioConcept, Allschwill, Switzerland), 50 U/ml penicillin,
50 μg/ml streptomycin, 1 mmol/l Na pyruvate and 250 μmol/l
HEPES, and thendissociated by incubationwith trypsin (5mg/ml
at 37°C for 4–5 min). Human pancreatic islets were obtained
from the Cell Isolation and Transplantation Center (University of
Geneva), through the ECIT ‘Islets for Research’ distribution
programme sponsored by the JDRF. The use of human islets
was approved by the Geneva institutional Ethics Committee.
Dissociated human islet cells prepared using the procedure de-
scribed above were cultured in CMRL medium (Invitrogen)
supplemented with 10% (vol./vol.) FCS, 100 U/ml penicillin,
100 μg/ml streptomycin, 2 mmol/l glutamine and 250 μmol/l
HEPES. Detailed information about the human islet preparations
used in this study is presented in electronic supplementary ma-
terial (ESM) Table 1.
MIN6B1 cell culture The murine insulin-secreting cell line
MIN6B1 [13] was cultured at a density of 1.5×105 cells/cm2
in DMEM-Glutamax medium (Invitrogen) supplemented
with 15% (vol./vol.) FCS, 50 U/ml penicillin, 50 μg/ml
streptomycin, and 70 μmol/l β-mercaptoethanol.
Transfection and modulation of miRNA levels MIN6B1 and
dissociated rat or human islet cells were transfected with
Lipofectamine 2000 (Invitrogen) with RNA oligonucleotide
duplexes (Eurogentec, Seraing, Belgium) corresponding to the
mature miRNA sequence (overexpression) or with single-
stranded miScript miRNA inhibitors (Qiagen, Hombrechtikon,
Switzerland) that specifically block endogenous miRNAs [14].
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A custom-designed small interfering (si)RNA duplex directed
against green fluorescent protein (sense 5′-GACGUAAACG
GCCACAAGUUC-3′ and antisense 5′-ACUUGUGGCCGU
UUACGU CGC-3′) and the miScript miRNA reference inhib-
itor (Qiagen) were used as negative controls for miRNA
overexpression and downregulation, respectively.
Measurement of miRNA and mRNA expression Mature
miRNA expression was assessed with the miRCURY
LNATM Universal RT MicroRNA PCR kit (Exiqon, Vedbaek,
Denmark). Measurement of the levels of putative target
mRNAs was performed by conventional reverse transcription
(Promega, Dübendorf, Switzerland) followed by quantitative
RT-PCR (qRT-PCR; Biorad, Reinach, Switzerland) with
custom-designed primers (Microsynth, Balgach, Switzerland),
details of which are available on request. MiRNA expression
was normalised to the level of U6 or miR-7 (an islet-specific
miRNA used as internal control) while mRNA expression was
normalised to 18S.
Insulin secretion At 2 days after transfection, MIN6B1 or
dissociated rat islet cells were pre-incubated for 30 min at
37°C in Krebs buffer (127 mmol/l NaCl, 4.7 mmol/l KCl,
1 mmol/l CaCl2, 1.2 mmol/l KH2PO4, 1.2 mmol/l MgSO4,
5 mmol/l NaHCO3, 0.1% [wt/vol.] BSA, 25 mmol/l HEPES,
pH 7.4) containing 2 mmol/l glucose. The pre-incubation me-
dium was discarded and the cells incubated for 45 min in the
same buffer (basal conditions). After collecting the supernatant
fractions, the cells were incubated for 45 min in Krebs buffer
containing 20 mmol/l glucose (stimulatory conditions). The
incubation medium was collected and total cellular insulin
contents recovered in acidified ethanol (75% [vol./vol.] ethanol,
0.55% [vol./vol.] HCl). The amount of insulin in the samples
was determined using an insulin enzyme immunoassay kit
(SPI-Bio, Bertin Pharma, Montigny le Bretonneux, France).
Cell death assessment Transfected MIN6B1, rat or human
dissociated islet cells were incubated with 1 μg/ml Hoechst
33342 (Invitrogen) for 1 min. The fractions of cells (at least
1×103 per condition) displaying pycnotic nuclei were scored
under fluorescence microscopy (AxioCam MRc5; Zeiss,
Feldbach, Switzerland). Apoptosis was triggered by expos-
ing the cells to cytokines (30 ng/ml INFγ, 10 ng/ml TNFα
and 0.1 ng/ml IL-1β) for 24 h or to medium (5% [vol./vol.]
FCS) supplemented with 0.5 mmol/l palmitate bound to
0.5% [wt/vol.] BSA [15] for 48 h.
Proliferation assay Transfected MIN6B1 or dissociated islet
cells cultured on poly-L-lysine-coated glass cover slips were
fixed with ice-cold methanol and permeabilised with 0.5%
(wt/vol.) saponin (Sigma-Aldrich, St Louis, MO, USA). The
cover slips were incubated with antibodies against Ki67
(1:500) (Abcam, Cambridge, UK) and insulin (1:500)
(Millipore, Zug, Switzerland) and then with anti-rabbit
Alexa-Fluor-488 and anti-mouse Alexa-Fluor-555 antibodies
(Invitrogen). At the end of the incubation, the cover slips were
washed with PBS containing Hoechst 33342 (Invitrogen) and
images of at least 1×103 cells per condition were collected
using a fluorescence microscope. PRL (500 ng/ml for 48 h)
was used as positive control.
Protein extraction and western blotting Protein lysates (30–
50 μg) from MIN6B1 cells prepared as described previously
[9] were separated on polyacrylamide gels and transferred to
polyvinylidine fluoride membranes. The membranes were
incubated overnight with antibodies against granuphilin [16]
(1:2,000); mammalian target of rapamycin (mTOR; 2972,
1:1,000 Cell Signaling, Danvers, MA, USA), met proto-
oncogene (hepatocyte growth factor receptor) (cMET; Cell
Signaling, 3127, 1:1,000) and glycogen synthase kinase 3β
(GSK-3β; Cell Signaling 9315, 1:1,000). Antibodies against
α-tubulin (T9026, 1:10,000, Sigma-Aldrich) and actin (Clone
C4 MAB1501, 1:15,000, Millipore) were used to verify equal
loading. After exposure to IRDye (Li-Cor Biosciences, Bad
Homburg, Germany) or horseradish-peroxidase-coupled sec-
ondary antibodies for 1 h, the bands were visualised via the
Odyssey imaging system (Li-Cor Biosciences) and chemilumi-
nescence (GE Healthcare Europe, Glattbrugg, Switzerland), re-
spectively. Band intensity was quantified by ImageJ software.
Statistical analysis Statistical differences were assessed using
a Student’s t test or, for multiple comparisons, one-way
ANOVA of the means, followed by a post-hoc Dunnett test
(SAS statistical package; SAS, Carry, NC, USA).
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Fig. 1 miRNAs differentially expressed in pancreatic islets of animal
models of type 2 diabetes. Pancreatic islets were isolated from predia-
betic (6 weeks old) and diabetic (14–20 weeks old) db/dbmice and from
HFD-fed mice. miRNA expression levels were analysed by microarray.
Data are expressed as fold changes vs the corresponding controls and
are presented on a logarithmic scale (log10). Only miRNAs displaying
increases (white circles) or decreases (black squares) of at least 1.5 fold
(p≤0.05) are plotted. Dashed lines correspond to a twofold change. Ctrl,
control
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Results
Islet miRNA expression in rodent models of type 2 diabetes To
investigate the contribution of miRNAs to beta cell dysfunc-
tion and the development of type 2 diabetes, we performed
global miRNA expression profiling in pancreatic islets
obtained from: db/db mice, which lack the leptin receptor
and develop severe obesity associated with type 2 diabetes
[10, 17]; and diet-induced obese mice, which display mild
hyperglycaemia and beta cell dysfunction after being fed an
HFD for 8 weeks [11]. The characteristics of the animals used
in this study are presented in ESM Tables 2–4. We identified
more than 60 differentially expressed miRNAs in db/db and
HFD-fed mice islets compared with their respective controls,
with overlapping changes in the two models (Fig. 1).
For db/db mice, miRNA expression was determined in
both prediabetic (6 weeks old) and diabetic (14–20 weeks
old) animals. In prediabetic mice, the miRNAs displaying
the most striking changes were miR-132, with expression
increasing by 8.2-fold, and miR-210, miR-184 and miR-203,
for which expression decreased by 4.0-, 3.4- and 2.0-fold,
respectively (ESM Table 5). In agreement with our previous
findings [9], the islets of prediabetic db/db mice contained
lower levels of miR-338-3p. The reduction of miR-210 and
miR-184 was more dramatic in the islets of overtly diabetic
db/db mice (10.4- and 115-fold decrease, respectively),
whereas upregulation of miR-132 and downregulation of
miR-203 and miR-338-3p remained approximately constant
in prediabetic and diabetic animals (ESM Tables 5 and 6). In
addition to these changes, the islets of adult diabetic mice were
characterised by alterations in the levels of additional
miRNAs, including an upregulation of miR-199a-5p (12.6-
fold) and miR-199a-3p (9.4-fold), a decline of miR-383 (13.7-
fold) and, as previously reported [6], an increase of miR-34a
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Fig. 2 Changes in miRNA
expression in islets of type 2
diabetes animal models. The
expression level of the indicated
miRNAs was measured by qRT-
PCR in pancreatic islets of young
prediabetic (a–d) and diabetic (e–l)
db/dbmice vs age-matched control
mice and in mice fed a normal diet
or HFD (m–s). The results
correspond to the mean ± SD of
three to four animals per group and
are normalised to the level of the
respective controls. *Significantly
different from control (control or
normal diet, as indicated) (p≤0.05
by unpaired Student’s t test). Ctrl,
control; ND, normal diet; yg,
young
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and miR-146a (ESM Table 6). The results obtained by micro-
array analysis were confirmed by qRT-PCR (Fig. 2a–l). Our
microarray data also revealed a 2.2-fold increase in miR-21,
which we have previously shown to inhibit insulin secretion
[8], a 1.6-fold decrease in miR-26a, which controls insulin
biosynthesis [18], and an increase in miR-802 (sixfold), which
regulates Hnf1b expression [19] (ESM Tables 6). The role of
these miRNAs was not further investigated in this study.
Islet miRNA expression was also analysed in HFD-fed
mice. For this purpose we selected the group of mice displaying
the strongest response to HFD. These animals were markedly
obese, insulin resistant, hyperinsulinaemic and clearly
hyperglycaemic (ESM Table 4). HFD mice showed miRNA
expression changes analogous to those observed in the islets of
diabetic db/db mice, with the exception of miR-21, miR-34a,
miR-146a, miR-199a-5p and miR-199a-3p, which were not
significantly modified (ESM Table 7 and Fig. 2m–s).
Overall, the data indicate that a subset of islet miRNAs is
similarly altered in two obesity-associated animal models of
type 2 diabetes, suggesting a role of specific miRNAs in beta
cell failure and the development of hyperglycaemia.
miRNA expression is affected by glucolipotoxic conditions To
determine the possible causes of the changes in miRNA ex-
pression detected in the islets of db/db and HFD-fed mice, we
tested whether the levels of these non-coding RNAs are affect-
ed by chronic exposure of beta cells to elevated concentrations
of glucose and NEFA. We found that prolonged incubation of
rat islets (Fig. 3) under glucolipotoxic conditions mimicked the
modifications in miR-132, miR-184, miR-199a-3p, miR-203
and miR-383 expression observed in animal models. In con-
trast, under these glucolipotoxic conditions the levels of miR-
210 and miR-199a-5p were not affected (Fig. 3).
Particular differentially expressed miRNAs influence beta cell
functions and survival Modifications of miRNA expression in
islets could reflect the activation of adaptive processes
counterbalancing the increased insulin needs caused by obesity
and insulin resistance or the onset of pathological conditions
leading to beta cell dysfunction. Indeed, we have previously
shown that downregulation of miR-338-3p contributes
to compensatory beta cell mass expansion [9], whereas
overexpression of miR-21, miR-34a and miR-146a negatively
impacts on beta cell function [6, 8]. To assess the possible role
of other differentially expressed miRNAs in these phenomena,
we mimicked the changes observed in the animal models by
transfecting dissociated rat islet cells and MIN6B1 cells with
oligonucleotide duplexes corresponding to the mature miRNA
sequences orwith anti-miRNAmolecules that specifically inhibit
miRNAs (ESM Fig. 1). The transfected cells were then analysed
for their functional properties.
We first assessed whether the miRNAs differentially
expressed in type 2 diabetes models are involved in the
regulation of insulin biosynthesis and release. Most of the
studied miRNAs did not affect insulin content (Fig. 4a–c) or
insulin release in dissociated rat islet cells (Fig. 4d–f) and
MIN6B1 cells (ESM Fig. 2). However, overexpression of
miR-132 resulted in improved glucose-stimulated insulin
release from dissociated rat islet cells (Fig. 4d). In contrast,
upregulation of miR-199a-5p led to an insulin secretory
defect in MIN6B1 cells (ESM Fig. 2), but not in islet cells,
where it only diminished the insulin content (Fig. 4a).
We next investigated whether the miRNAs differentially
expressed in type 2 diabetes models regulate beta cell ex-
pansion. In MIN6B1 cells, upregulation of miR-132 or
downregulation of miR-184, miR-203 and miR-383 led to
an increase in proliferation while modification of the levels
of other miRNAs had no significant effects (ESM Fig. 3).
Proliferation of insulin-positive cells was also observed on
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Fig. 3 Effect of chronically elevated glucose and palmitate on the level
of islet miRNAs differentially expressed in type 2 diabetes animal
models. Isolated rat islets were incubated at 11 or 20 mmol/l glucose
with 0.5% BSA in the absence (black bars) or presence of 0.5 mmol/l
palmitate for 48 h (grey bars) or 72 h (white bars). miRNA expression
levels were measured by qRT-PCR, normalised by miR-7 and expressed
as percentage of control (11 mmol/l glucose with 0.5% BSA) (a–g).
*Significantly different from control condition, p≤0.05 by ANOVA anal-
ysis, Dunnett’s post-hoc test. 11 G, 11 mmol/l glucose; 20 G, 20 mmol/l
glucose; Ctrl, control
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upregulation of miR-132 (Fig. 5a) and, to a lesser extent,
downregulation of miR-184 in dispersed rat islet cells
(Fig. 5b). In contrast, downregulation of miR-203 and
miR-383 in primary cells had no effect (Fig. 5c, d). Similar
to our previous work with miR-338-3p [9], these findings
suggest that modification of the levels of miR-132 and miR-
184 contributes to compensatory beta cell mass expansion
elicited in response to insulin resistance.
As an increase in beta cell apoptosis and a reduction in beta
cell mass are thought to play a role in the development of type 2
diabetes [20], we investigated the impact of miRNAs of interest
on beta cell survival. As previously observed for miR-34a and
miR-146a [6], upregulation of miR-199a-3p or reduction of
miR-203, miR-210 and miR-383 expression increased the
number of apoptotic MIN6B1 cells (ESM Fig. 4) as well as
dispersed rat islet cells (Fig. 6a, c, e). Similar results were
obtained using dissociated human islet cells (Fig. 6b, d, f). In
contrast, overexpression of miR-132 or silencing of miR-184
did not induce beta cell death, but rather protected dispersed rat
(Fig. 7a–d) and human (Fig. 7e–h) islet cells from apoptosis
when the cells were chronically exposed to elevated concen-
trations of NEFA or to proinflammatory cytokines. Analogous
results were also obtained in MIN6B1 cells (ESM Fig. 5).
Impact of particular miRNA changes on candidate target
gene expression As described above, db/db mouse islets are
characterised by a specific rise in the levels of miR-21, miR-
34a, miR-146a, miR-199a-3p and -5p and a downregulation of
miR-203, miR-210 and miR-383 that possibly result in beta
cell dysfunction and death. We previously found that miR-34a
affects beta cell survival by directly targeting the anti-apoptotic
protein B cell CLL/lymphoma 2 (BCL2) [6]. Combining
An
ti-c
trl
An
ti-m
iR-
18
4
0
1
2
3
Ki
67
-p
os
itiv
e 
ce
lls
(%
 of
 in
s.-
po
siti
ve
 ce
lls)
Ctr
l
m
iR-
13
2
PR
L
0
2
4
6
8
a b
c d
Ki
67
-p
os
itiv
e 
ce
lls
(%
 
of
 
in
s.
-
po
sit
ive
 
ce
lls
)
*
*
*
An
ti-c
trl
An
ti-m
iR-
20
3
0
1
2
3
Ki
67
-p
os
itiv
e 
ce
lls
(%
 of
 in
s.-
po
sit
ive
 ce
lls
)
An
ti-c
trl
An
ti-m
iR-
38
3
0
1
2
3
Ki
67
-p
os
itiv
e 
ce
lls
(%
 of
 in
s.-
po
sit
ive
 ce
lls
)
Fig. 5 Effect of specific modifications in miRNA expression on beta
cell proliferation. Dispersed rat islet cells were transfected with oligo-
nucleotides leading to overexperession (a) or downregulation (b–d) of
the indicated miRNAs. Beta cell proliferation was assessed 72 h later by
staining the cells with anti-Ki67 and anti-insulin antibodies. PRL
(500 ng/ml for 48 h, grey bars) was used as positive control. The results
correspond to the mean ± SD of three to six independent experiments.
*Significantly different from control condition (control or anti-control,
as shown), p≤0.05 by ANOVA analysis, Dunnett’s post-hoc test. Ctrl,
control; ins., insulin
Ctr
l
m
iR-
13
2
m
iR-
19
9a
-5p
0
200
400
600
800
1,000
In
su
lin
 c
on
te
nt
(ng
 
in
su
lin
/w
el
l)
*
An
ti-c
trl
An
ti-m
iR-
20
3
An
ti-m
iR-
38
3
0
200
400
600
800
In
su
lin
 co
nt
en
t
(ng
 in
su
lin/
we
ll)
An
ti-c
trl
An
ti-m
iR-
18
4
An
ti-m
iR-
21
0
0
200
400
600
800
In
su
lin
 co
nt
en
t
(ng
 in
su
lin/
we
ll)
Ctr
l
m
iR-
13
2
m
iR-
19
9a
-5p
0
2
4
6
8
In
su
lin
 re
lea
se
(%
 of
 IC
)
*
An
ti-c
trl
An
ti-m
iR-
18
4
An
ti-m
iR-
21
0
0
2
4
6
8
In
su
lin
 re
lea
se
(%
 of
 IC
)
An
ti-c
trl
An
ti-m
iR-
20
3
An
ti-m
iR-
38
3
0
2
4
6
8
In
su
lin
 re
lea
se
(%
 of
 IC
)
a
d e f
b cFig. 4 Impact of changes in
miRNA expression on insulin
content and insulin secretion.
Dispersed rat islet cells were
transfected with oligonucleotides
leading to overexpression (a, d)
or downregulation (b, c, e, f) of
the indicated miRNAs. Insulin
content (a–c) and insulin
secretion (d–f) in response to 2
(black bars) or 20 (white bars)
mmol/l glucose were measured
48 h post-transfection. Insulin
release is expressed as
percentage of insulin content.
*Significantly different from
control condition (control or
anti-control, as shown, incubated
at the same glucose
concentration), p≤0.05 by
ANOVA analysis, Dunnett’s
post-hoc test. Ctrl, control; IC,
insulin content
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bioinformatics-prediction algorithms (http://mirsystem.cgm.
ntu.edu.tw/) and a literature search, we identified other
miRNA targets potentially explaining the functional effects
observed. In hepatocytes, miR-199a-3p regulates the expres-
sion of mTOR and of the transcription factor cMET [21], two
proteins known to play important roles in the control of beta
cell mass and survival [22, 23]. We found that upregulation of
miR-199a-3p results in decreased expression of mTOR and
cMETalso in MIN6B1 cells (ESM Fig. 6), possibly explaining
the negative impact of this miRNA on beta cell survival.
Increased expression of miR-132 displays beneficial ef-
fects on both beta cell mass and function. Computational
prediction algorithms (http://mirsystem.cgm.ntu.edu.tw/) in-
dicate that granuphilin (also known as synaptotagmin-like 4
[SLP-4]), a granule-associated protein that negatively affects
insulin release [16], and GSK-3β, which negatively regulates
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Fig. 6 Impact of specific miRNA expression changes on islet cell
survival. Dissociated rat (a, c, e) and human (b, d, f) islet cells were
transfected with the indicated miRNA mimics (a, b) or anti-miRNAs
(c–f). Cell death was assessed by scoring the cells displaying pycnotic
nuclei on Hoechst staining. Incubation for 24 h with a mix of
proinflammatory cytokines was used as a positive control for apoptosis
(grey bars). The results correspond to the mean ± SD of three to four
independent experiments. *Significantly different from control condi-
tion (ctrl or anti-ctrl, as shown), p≤0.05 by ANOVA analysis, Dunnett’s
post-hoc test. Ctrl, control; cyt. mix, proinflammatory cytokine mixture
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Fig. 7 Overexpression of miR-132 and inhibition of miR-184 protects
beta cells against palmitate- or cytokine-induced apoptosis. Dissociated
rat (a–d) or human (e–h) islet cells were transfected with miR-132
mimic or with anti-miR-184. The cells were then incubated for 48 h
with (white bars) or without (black bars) 0.5 mmol/l palmitate coupled
to 0.5% BSA (a, b, e, f), or for 24 h with (grey bars) or without (black
bars) a mix of proinflammatory cytokines (c, d, g, h). Apoptosis was
assessed at 48 h post-transfection by Hoechst staining of pycnotic
nuclei. The results correspond to the mean ± SD of three to four
independent experiments. *Significantly different from treated control
condition (control or anti-control, as shown), p≤0.05 by ANOVA
analysis, Dunnett’s post-hoc test. Ctrl, control
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beta cell function and mass [24, 25], are potential miR-132
targets. Translational repression of these two genes could
explain, at least in part, the phenotypic traits of beta cells
overexpressing miR-132. However, western blot analysis did
not reveal any significant impact of miR-132 on the level of
these proteins in MIN6B1 cells (ESM Fig. 6). MiRNAs often
have small impacts on the expression of single direct targets
[26]. However, cumulative effects can have major indirect
influences on gene expression and cellular activities. Thus,
instead of searching for direct targets, we measured the cellu-
lar level of a group of transcription factors known from the
literature to improve survival and function of beta cells
[27–29]. We found that upregulation of miR-132 in rat islet
cells did not affect the mRNA levels of Foxm1 and Pdx1 but
increased the level ofMafa (Fig. 8b). Downregulation of miR-
184 that induces overlapping phenotypic changes did not alter
the expression level of these genes (not shown).
Discussion
We have identified two groups of miRNAs displaying dif-
ferential expression in pancreatic islets isolated from two
animal models characterised by obesity, insulin resistance
and beta cell dysfunction: db/db mice and HFD-fed mice.
The changes in expression of miR-21, miR-34a, miR-132,
miR-146a, miR-184, miR-210 and miR-383 detected in this
study are consistent with those described by Zhao et al in the
islets of leptin-deficient ob/ob mice [5] and are in agreement
with previous findings from our laboratory [6, 8]. Elevated
miR-21 levels were also detected in islets of glucose-
intolerant human donors [30]. Moreover, our microarray data
confirm the upregulation of miR-802 in the islets of db/db
mice recently observed by Kornfeld et al [19]. Increased
expression of miR-132, miR-199a-5p and miR-199a-3p
have also been reported in the islets of GK rats, a lean model
of type 2 diabetes [7]. Consistent with results obtained in
ob/obmice [5], our microarray data did not reveal significant
changes in the level of many miRNAs that play important
roles in the control of beta cell functions, including miR-9,
miR-24, miR-124a and miR-148 [18, 31–33]. Moreover, we
did not detect differences in the levels of miR-375, an islet-
enriched miRNA that regulates insulin secretion and beta
cell proliferation and that is slightly upregulated (about 30%)
in ob/obmice [34]. Thus, although appropriate expression of
these miRNAs is required for ensuring optimal beta cell
function, the development of type 2 diabetes appears not to
be associated with major changes in the level of these non-
coding RNAs. However, individuals expressing inappropri-
ate levels of these miRNAs may display defective beta cell
functions [30] and may be more susceptible to type 2 diabe-
tes manifestation. Indeed, ob/ob mice lacking miR-375 de-
velop diabetes [34].
The analysis of the functional impact of individual changes in
miRNA expression in isolated islet cells revealed that some of
them have beneficial effects on the activity of insulin-secreting
cells whereas others result in beta cell death. Upregulation of
miR-132 and downregulation of miR-184 and miR-338-3p are
already observed in 6 week-old prediabetic obese db/db mice.
These adaptive changes in miRNA expression that have a
positive impact on beta cell functions are conserved or even
more pronounced in HFD-fed and 14–20-week-old diabetic
db/db mice. Indeed, when the level of these particular
miRNAs was modulated in vitro, both tumoral and normal beta
cells displayed enhanced proliferation and resistance to pro-
apoptotic stimuli (present study and Jacovetti et al [9]).
Moreover, a rise in the level of miR-132 improved the secretory
response of the cells to glucose. These observations suggest that
adaptive expression of miR-132, miR-184 andmiR-338-3pmay
contribute to beta cell compensation processes.
The increasedmiR-132 content and the decreased miR-184
expression observed in db/db and HFD-fed mice were mim-
icked by incubation of dissociated rat islet cells in the presence
of chronically elevated concentrations of palmitate and glu-
cose. This suggests that these miRNAs may be induced in
response to hyperglycaemia and hyperlipidaemia, two condi-
tions typically encountered in prediabetic and diabetic states.
In neurons, the expression of miR-132 is triggered following
activation of the cAMP-dependent pathway and of the tran-
scription factor cAMP response element-binding protein
(CREB) [35–40]. Incubation of rat insulinoma INS-1 832/13
cells with cAMP-raising agents has been shown to cause a
rapid increase in the miR-132 precursor [41], indicating that a
similar regulatory mechanism may also operate in beta cells.
The mechanisms underlying the effects caused by changes
in the level of miR-132 and miR-184 remain to be fully
elucidated. We found that upregulation of miR-132 in disso-
ciated rat islet cells leads to increased expression of Mafa, a
gene playing an important role in the control of beta cell
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Fig. 8 Effect of mir-132 overexpression on the level of key beta cell
transcription factors. Dissociated rat islet cells were transfected with
control (black bars) or miR-132 oligonucleotide mimics (white bars).
Two days after transfection, the levels of miR-132 (a) andMafa, Foxm1
and Pdx1 mRNAs (b) were analysed by qRT-PCR. The results corre-
spond to the mean ± SD of at least three independent experiments.
*Significantly different from control condition, p≤0.05 by ANOVA
analysis, Dunnett’s post-hoc test. Ctrl, control
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function and survival [28]. The expression of this transcription
factor is decreased by palmitate [42] and is strongly reduced in
the islets of diabetic db/db mice [10, 43]. Moreover, nuclear
MAFAwas recently reported to be diminished in the islets of
individuals affected by type 2 diabetes [44]. Our data suggest
that the induction of miR-132 helps preserve the level of
MAFA during obesity-associated beta cell compensation.
Over the long term, the adaptive changes elicited bymiR-132,
miR-184 and miR-338-3p may become insufficient to counter-
balance insulin resistance; alterations in the levels of additional
miRNAs with deleterious impacts on beta cells also add to the
effect. Indeed, the islets of HFD-fed and of diabetic db/db mice
displayed changes in the levels of several other miRNAs, includ-
ing miR-21, miR-34a, miR-146a, miR-199a-5p, miR-199a-3p,
miR-203,miR-210 andmiR-383; variation in expression of these
miRNAs in vitro causes beta cell dysfunction and death (Lovis
et al [6], Roggli et al [8] and present study). We previously
showed that induction of miR-34a and miR-146a triggers beta
cell apoptosis and that miR-21 and miR-34a have a deleteri-
ous impact on insulin secretion [6, 8]. Experiments
carried out in this study revealed an increase in apopto-
sis after overexpression of miR-199a-3p or downregulation of
miR-203, miR-210 and miR-383 in dissociated rat and human
islet cells and in MIN6B1 cells. These phenotypic changes are
not unique to beta cells as modifications in the level of some of
these miRNAs promote apoptosis in other cell systems [21,
45–47]. Overexpression ofmiR-199a-3p resulted in a reduction
of the levels of mTOR and cMET, two well-characterised
targets of this miRNA [21, 48]. Disruption of the signalling
pathways involving these two proteins is detrimental for beta
cells [23, 49]. Moreover, mTOR is an important regulator of
autophagy, a process thought to contribute to type 2 diabetes
onset [50]. Thus, the toxic effects of miR-199a-3p may be the
consequence of diminished expression of mTOR and cMET.
In conclusion, the present study is the first globally address-
ing the role of miRNAs in the aetiology of type 2 diabetes by
systematically investigating the impact on primary beta cell
function of miRNA changes observed in two animal models
of obesity-associated diabetes. Our data demonstrate that obesity
and insulin resistance are associated with modifications in two
distinct groups of islet miRNAs that have opposing phenotypic
effects on beta cells. Expression changes in miRNAs promoting
beta cell mass expansion and boosting glucose-induced insulin
secretion already occur in normoglycaemic animals and proba-
bly belong to adaptive processes allowing beta cells to compen-
sate for insulin resistance. If these mechanisms fail to compen-
sate for the diminished insulin sensitivity, additional modifica-
tions in miRNA expression may accumulate, causing beta cell
failure and manifestation of type 2 diabetes. We propose that
beta cell activities are tuned by a balance between the levels of
particular miRNAs associated with enhanced function and
mass, such as miR-132, miR-184 and miR-338-3p, and
others having negative impacts, including miR-21, miR-
34a, miR-146a, miR-199a-5p, miR-199a-3p, miR-203, miR-
210 and miR-383. A better understanding of the precise role
of particular miRNAs involved in the natural history of
the beta cell in diabetes may be harnessed to design novel
therapeutic strategies for diabetes prevention and treatment.
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